CD25 antibodies

CD25 antibodies

Clone: 4E3
4E3 recognizes the human CD25 antigen, a 55 kDa glycoprotein also known as the low-affinity interleukin-2 receptor alpha chain (IL-2Rα). CD25 is expressed on activated T and B cells, on macrophages, and on a subset of non-activated CD4
+
regulatory T cells. The CD25 antigen contains three epitope regions called A, B, and C. This CD25 antibody recognizes epitope region B.

Alternative names

IL-2Rα, p55, Tac

Technical specifications

  • Antigen: CD25
  • Clone: 4E3
  • Isotype: mouse IgG2b
  • Alternative names of antigen: IL-2Rα, p55, Tac
  • Molecular mass of antigen [kDa]: 28
  • Distribution of antigen: B cells, basophils, lymphocytes, macrophages, monocytes, myeloid cells, NK cells, osteoblasts, T cells, thymocytes
  • Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
  • Storage: Store protected from light at 2–8 °C (36–46 °F). Do not freeze.
  • Available conjugates: PE, APC
  • Selected references

    1. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
    2. Sakaguchi, S. et al. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164
    3. Lamprecht, B. et al. (2008) Aberrant expression of the Tʜ2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112(8): 3339-3347
    4. Maloy, K. J. et al. (2001) Regulatory T cells in the control of immune pathology. Nat. Immunol. 2(9): 816-822
    5. Shevach, E. M. (2001)
      Certified professionals: CD4
      +
      CD25
      +
      suppressor T cells.
      J. Exp. Med. 193(11): F41-F46
    6. Wood BL et al. (2007) 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin. Cytom. 72: 14-22
    7. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
    8. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
    9. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
    10. Knapp, W. et al. (eds) Leukocyte Typing IV Oxford, Oxford University Press
    11. Chaput, N. et al. (2013)
      Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR
      +
      NK cell levels correlate with disease outcome.
      Oncoimmunology 2(2): e23080
    12. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
  • Certificates

    Please follow this
    link
    to search for Certificates of Analysis (CoA) by lot number.
Product options: 2
170-081-050

CD25-APC

1 mL
EUR  420,00
170-081-029

CD25-PE

1 mL
EUR  420,00